ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

AMO959

A development code. Also written as “BY101298 Capsules”.

In Novartis’s pipeline, DNA PK inhibitor. Its studies are mostly in Prostatic Neoplasms, led by 2 companies.

Furthest: phase 2, since Jun 12, 20242 company-led studies, 2 open or runningNext primary completion: Jul 10, 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Chengdu Baiyu Pharmaceutical11 open or runningphase 1since Jun 12, 2024Jun 12, 2024none ahead
Novartisits history only11 open or runningphase 2since Nov 7, 2025Nov 7, 2025Jul 10, 2028phase 2 · NCT07226986
  • Named in Novartis’s own pipeline as AMO959, phase 1, as of Nov 16, 2026 (source).

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Chengdu Baiyu Pharmaceutical only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 12, 2024First study: phase 1 study in Solid Tumor, AdultFirst studyNCT06462716 · 36 enrolled · China

TargetBeta

“DNA PK inhibitor”the company's pipeline, read by Claude · source

Other programs on PRKDC

ProgramCompanyFurthest phaseStudies
bosmolisibruleBoryung Pharmaceuticalphase 22

Studies

The one study Chengdu Baiyu Pharmaceutical leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06462716Solid Tumor, Adult · China1Active, not recruitingDec 31, 202436

How it is read

Names in the registry

  • “AMO959”, 1 entry
  • “BY101298 Capsules”, 1 entry

Codes read as this program: AMO959, BY101298.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.